2024-06-12 09:00:00 ET
Summary
- Kenvue is a stock with a 4.4% yield and potential for long-term growth as a result of their strong brands like Tylenol, Neutrogena, and Listerine.
- The company reported solid earnings and organic growth in a challenging environment.
- Kenvue's segments showed mixed results, with solid growth in two of its three segments.
- Earnings are expected to decline year-over-year from $1.29 to $1.15 at midpoint. However, management expects the company to deliver strong earnings growth in 2025 onward.
- KVUE has a strong balance sheet with well-laddered debt maturities that they can refinance lower rates if interest rates drop as expected.
Introduction
Kenvue ( KVUE ) is a stock I opened a position in shortly after the consumer staple spun-off from its parent company, Johnson & Johnson ( JNJ ). The stock is yielding more than 4% currently and has all the makings of a quality, long-term holding that will likely reward those willing to remain patient for the long-term....
Read the full article on Seeking Alpha
For further details see:
Kenvue: A 4% Yield Worth Going Long